Palvella Therapeutics, Inc. (NASDAQ:PVLA)
| Market Cap | 1.80B+77.6% |
| Revenue (ttm) | 0 |
| Net Income | -61.70M-117.4% |
| EPS | -4.83+36.5% |
| Shares Out | 14.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 161,791 |
| Open | 125.53 |
| Previous Close | 126.39 |
| Day's Range | 121.34 - 125.93 |
| 52-Week Range | 68.96 - 161.38 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 228.50(+82.65%) |
| Earnings Date | Nov 10, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$PVLA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in PVLA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PVLA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PVLA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New PVLA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PVLA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PVLA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $53.86M |
| XBIState Street SPDR S&P Biotech ETF | $48.80M |
| IWMiShares Russell 2000 ETF | $37.79M |
| IWOiShares Russell 2000 Growth ETF | $14.04M |
| VTWOVanguard Russell 2000 ETF | $9.55M |
| SCHASchwab U.S. Small-Cap ETF | $8.16M |
Estimated from each fund’s disclosed top holdings × AUM
PVLA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from PVLA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score